- Home
- PLSM vs ATRA Comparison
PLSM vs ATRA Comparison
Compare PLSM & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSM | ATRA |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.5M | 38.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PLSM | ATRA |
|---|---|---|
| Price | $3.34 | $4.89 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 7.4K | ★ 229.0K |
| Earning Date | 03-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.94 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.21 | $3.92 |
| 52 Week High | $6.85 | $19.15 |
Technical Indicators
Market Signals| Indicator | PLSM | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 26.31 | 46.83 |
| Support Level | N/A | $4.70 |
| Resistance Level | $4.30 | $5.65 |
| Average True Range (ATR) | 0.30 | 0.45 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 10.24 | 32.09 |
Price Performance
Historical ComparisonAbout PLSM Pulsenmore Ltd. Ordinary Shares
Pulsenmore Ltd is engaged in developing portable ultrasound devices for home use. Its ultrasound scanner dock's with patients' smartphones to deliver images that can be created anywhere, stored and forwarded for clinical review, or shared in an online consultation.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).